- Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II studyZhou, Q.; Meng, X.; Sun, L.; Huang, D.; Yang, N.; Yu, Y.; Zhao, M.; Zhuang, W.; Hu, Y.; Pan, Y.; Sun, M.; Shan, J.; Guo, R-H.; Chu, Q.; Xu, C.; Lin, J.; Huang, J.; Huang, M.; Shen, Y.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.Lin, Shengcheng; Ma, Kai; Xu, Yafei; Liu, Xinyi; Huang, Xiaochun; Huang, MengliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- KRAS G12 subtypes with co-mutated TP53, LRP1B, STK11, KEAP1 in lung cancer and their impact on TMB levels, PD-L1 expression and overall survivalZhao, Y.; Wu, X.; Tang, H.; Qi, Q.; Zhang, C.; Liu, X.; Huang, M.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
会议论文
Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
1被引6阅读
